Literature DB >> 28079545

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Alberto Borghetti1, Gianmaria Baldin, Amedeo Capetti, Gaetana Sterrantino, Stefano Rusconi, Alessandra Latini, Andrea Giacometti, Giordano Madeddu, Chiara Picarelli, Ramona De Marco, Maria V Cossu, Filippo Lagi, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28079545     DOI： 10.1097/QAD.0000000000001357

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  BAGEL: A BAYESIAN GRAPHICAL MODEL FOR INFERRING DRUG EFFECT LONGITUDINALLY ON DEPRESSION IN PEOPLE WITH HIV.

Authors:  Yuliang Li; Yang Ni; Leah H Rubin; Amanda B Spence; Yanxun Xu
Journal:  Ann Appl Stat       Date:  2022-03-28       Impact factor: 1.959

2.  Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.

Authors:  Noelia Fernández-Bargiela; Sandra Rotea-Salvo; Luis Margusino-Framiñán; Vanesa Balboa-Barreiro; Isabel Martín-Herranz; Ángeles Castro-Iglesias; Álvaro Mena-De-Cea; Soledad López-Calvo; Pilar Vázquez-Rodríguez; Enrique Míguez-Rey; Purificación Cid-Silva
Journal:  Eur J Hosp Pharm       Date:  2020-10-13

3.  Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.

Authors:  Leah H Rubin; Jane A O'Halloran; Dionna W Williams; Yuliang Li; Kathryn C Fitzgerald; Raha Dastgheyb; Alexandra L Damron; Pauline M Maki; Amanda B Spence; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Yanxun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2022-02-17       Impact factor: 7.285

4.  Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort.

Authors:  Paolo Bonfanti; Andrea De Vito; Elena Ricci; Barbara Menzaghi; Giancarlo Orofino; Nicola Squillace; Chiara Molteni; Giuseppe Vittorio De Socio; Elena Salomoni; Benedetto Maurizio Celesia; Chiara Dentone; Valeria Colombo; Giordano Madeddu
Journal:  Infect Drug Resist       Date:  2020-07-14       Impact factor: 4.003

5.  Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.

Authors:  Andrea De Vito; Annarita Botta; Marco Berruti; Valeria Castelli; Vincenzo Lai; Chiara Cassol; Alessandro Lanari; Giulia Stella; Adrian Shallvari; Antonia Bezenchek; Antonio Di Biagio
Journal:  J Pers Med       Date:  2022-01-31

6.  Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.

Authors:  Dionna W Williams; Yuliang Li; Yanxun Xu; Leah H Rubin; Raha Dastgheyb; Kathryn C Fitzgerald; Pauline M Maki; Amanda B Spence; Deborah R Gustafson; Joel Milam; Anjali Sharma; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Kathleen M Weber
Journal:  J Neuroimmune Pharmacol       Date:  2020-01-13       Impact factor: 7.285

7.  Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2.

Authors:  U Naumann; A Moll; D Schleehauf; K T Lutz; W Schmidt; H Jaeger; B Funke; V Witte
Journal:  Int J STD AIDS       Date:  2019-06       Impact factor: 1.359

8.  Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).

Authors:  Arturo Ciccullo; Gianmaria Baldin; Amedeo Capetti; Vanni Borghi; Gaetana Sterrantino; Alessandra Latini; Giordano Madeddu; Luigi Celani; Francesca Vignale; Barbara Rossetti; Alex Dusina; Maria Vittoria Cossu; Sibilla Restelli; William Gennari; Filippo Lagi; Andrea Giacomelli; Manuela Colafigli; Lucia Brescini; Alberto Borghetti; Cristina Mussini; Stefano Rusconi; Simona Di Giambenedetto
Journal:  BMJ Open       Date:  2019-12-02       Impact factor: 2.692

9.  Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV.

Authors:  Lisa Van de Wijer; Wouter van der Heijden; Mike van Verseveld; Mihai Netea; Quirijn de Mast; Arnt Schellekens; André van der Ven
Journal:  AIDS Behav       Date:  2021-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.